Development, validation and application of ELISAs for pharmacokinetic and HACA assessment of a chimeric anti-CD40 monoclonal antibody in human serum

Journal of Immunological Methods

Volumn 363, Issue 1, 2010, Pages 1-8

  Chowdhury, F ^a   Tutt, A L ^a   Chan, C ^a   Glennie, M ^a   Johnson, P W ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

ELISA; HACA; Immunogenicity; Pharmacokinetic; Validation

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY; CHIMERIC ANTIBODY;

ARTICLE; BIOTINYLATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOGENICITY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SERUM; VALIDATION PROCESS;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; CHO CELLS; CRICETINAE; CRICETULUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MONITORING, PHYSIOLOGIC; SENSITIVITY AND SPECIFICITY;

EID: 78649702542     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2010.09.023     Document Type: Article

References (17)

1. Abarca K., Jung E., Fernandez P., Zhao L., Harris B., Connor E.M., Losonsky G.A. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children. Pediatr. Infect. Dis. J. 2009, 28:267.
2. Chau C.H., Rixe O., McLeod H., Figg W.D. Validation of analytic methods for biomarkers used in drug development. Clin. Cancer Res. 2008, 14:5967.
3. Chowdhury F., Williams A.P. From research to regulated: challenges in transferring methods. Bioanalysis 2010, 1:285.
4. Damen C.W., de Groot E.R., Heij M., Boss D.S., Schellens J.H., Rosing H., Beijnen J.H., Aarden L.A. Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma. Anal. Biochem. 2009, 391:114.
5. DeSilva B., Smith W., Weiner R., Kelley M., Smolec J., Lee B., Khan M., Tacey R., Hill H., Celniker A. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 2003, 20:1885.
6. Findlay J.W., Smith W.C., Lee J.W., Nordblom G.D., Das I., DeSilva B.S., Khan M.N., Bowsher R.R. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J. Pharm. Biomed. Anal. 2000, 21:1249.
7. Jamieson D., Cresti N., Verrill M.W., Boddy A.V. Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma. J. Immunol. Methods 2009, 345:106.
8. Koren E., Zuckerman L.A., Mire-Sluis A.R. Immune responses to therapeutic proteins in humans-clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 2002, 3:349.
9. Lee J.W., Devanarayan V., Barrett Y.C., Weiner R., Allinson J., Fountain S., Keller S., Weinryb I., Green M., Duan L., Rogers J.A., Millham R., O'Brien P.J., Sailstad J., Khan M., Ray C., Wagner J.A. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 2006, 23:312.
10. Mander A., Chowdhury F., Low L., Ottensmeier C.H. Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines. Cancer Immunol. Immunother. 2009, 58:789.
11. Maple L., Lathrop R., Bozich S., Harman W., Tacey R., Kelley M., Danilkovitch-Miagkova A. Development and validation of ELISA for herceptin detection in human serum. J. Immunol. Methods 2004, 295:169.
12. Martin B.B., Marquet P., Ferrer J.M., Puig B.C., Bennasar A.B., Prieto M.R., Marques R.F. Rheumatoid factor interference in a tacrolimus immunoassay. Ther. Drug Monit. 2009, 31:743.
13. Mire-Sluis A.R., Barrett Y.C., Devanarayan V., Koren E., Liu H., Maia M., Parish T., Scott G., Shankar G., Shores E., Swanson S.J., Taniguchi G., Wierda D., Zuckerman L.A. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 2004, 289:1.
14. Muller P.Y., Brennan F.R. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies. Clin. Pharmacol. Ther. 2009, 85:247.
15. Tatarewicz S., Moxness M., Weeraratne D., Zhou L., Hale M., Swanson S.J., Chirmule N. A step-wise approach for transfer of immunogenicity assays during clinical drug development. AAPS J. 2009, 11:526.
16. Van W.I., Gansemans Y., Parren P.W., Stas P., Lasters I. Immunogenicity screening in protein drug development. Expert Opin. Biol. Ther. 2007, 7:405.
17. White J.T., Martell L.A., Van T.A., Boyer R., Warness L., Taniguchi G.T., Foehr E. Development, validation, and clinical implementation of an assay to measure total antibody response to naglazyme (galsulfase). AAPS J. 2008, 10:363.